Floatz logo

Spartalizumab

Pancreatic Carcinoma

Novartis Pharmaceuticalsmonoclonal_antibodyPhase 1/2Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
81/ 100

Competitive context

104 Active assets in the Pancreatic Carcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
OHSU Knight Cancer Institute
Phase 2/3BBB
Irinotecan
OHSU Knight Cancer Institute
Phase 2/3BBB
FLUOROURACILUM
Northwestern University
Phase 2/3BBB
Gdc-0449
OHSU Knight Cancer Institute
Phase 2BB
Capecitabine
Zhejiang University
Phase 2BB

View all 50 →

Same molecule, other indications

Spartalizumab is also rated in:

pancreatic adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
triple-negative breast carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
melanomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →